Outcomes with erlotinib (Tarceva®) in a Yorkshire cancer centre

被引：0
|
作者：
O'Toole, L. [1 ]
Bond, M. [1 ]
Snee, M. [1 ]
机构：
[1] Cookridge Hosp, Leeds LS16 6QB, W Yorkshire, England
来源：
LUNG CANCER | 2007年 / 57卷
关键词：
D O I：
10.1016/S0169-5002(07)70350-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24
引用
收藏
页码：S7 / S7
页数：1
相关论文
共 50 条
  • [21] What do we know about dosing Tarceva™ based on erlotinib pharmacokinetics in cancer patients?
    Wolf, J
    Lu, J
    Lum, B
    Zborowski, D
    Rakhit, A
    Clark, G
    Ptaszynski, M
    Hamilton, M
    LUNG CANCER, 2005, 49 : S373 - S373
  • [22] A case of trichomegaly of the eyelashes and facial hypertrichosis induced by erlotinib (Tarceva®)
    Marquez, Gemma
    Herrera-Acosta, Enrique
    Vidal, Isabel
    Galvany, Loida
    Iglesias, Maribel
    Umbert, Pablo
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2009, 48 (01) : 97 - 98
  • [23] Pathogenesis and management of Erlotinib (Tarceva®) -: induced cutaneous side effects
    Gerber, P. A.
    Enderlein, E.
    Ansari, P.
    Homey, B.
    EXPERIMENTAL DERMATOLOGY, 2007, 16 (03) : 243 - 244
  • [24] Challenges and opportunities for erlotinib (Tarceva): What does the future hold?
    Hortobagyi, GN
    Sauter, G
    SEMINARS IN ONCOLOGY, 2003, 30 (03) : 47 - 53
  • [25] Preclinical studies with erlotinib (Tarceva) (vol 30, pg 16, 2003)
    Akita, RW
    Sliwkowski, MX
    SEMINARS IN ONCOLOGY, 2003, 30 (06) : 826 - 826
  • [26] Yorkshire Scholarship Centre
    不详
    DANCING TIMES, 2007, 97 (1157): : 75 - 75
  • [27] Survival benefit from erlotinib (TARCEVA®) in NSCLC patients with good prognostic factors
    Cagnoni, Pablo
    Christy-Bittel, Janna
    McCarthy, Sean
    Clark, Gary
    ANNALS OF ONCOLOGY, 2006, 17 : 235 - 235
  • [28] Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib (Tarceva™) in lung cancer patients
    Amler, Lukas C.
    Januario, Thomas
    Eberhard, David
    Cavet, Guy
    Zhu, Wenjing
    Fu, Ling
    Pham, Thinh Q.
    Soriano, Robert
    Stinson, Jeremy
    Seshagiri, Somasekar
    Modrusan, Zora
    Lin, Chin-Yu
    O'Neill, Vincent
    Yauch, Robert L.
    CANCER RESEARCH, 2006, 66 (08)
  • [29] Modulation of the radiosensitivity of U343 glioblastoma cells through erlotinib (Tarceva)
    Milanovic, D.
    Lohr, F.
    Wertz, F.
    Herskind, C.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2006, 182 : 84 - 84
  • [30] Phase II trial of erlotinib (Tarceva) in women with squamous cell carcinoma of the vulva
    Horowitz, N.
    Olawaiye, A.
    Growdon, W.
    Borger, D.
    Dizon, D.
    Brard, L.
    Matulonis, U.
    MacNeill, K.
    Roche, M.
    Krasner, C.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S14 - S14
12345